COLLABORATION TO DEVELOP EVIDENCE-BASED STRATEGIES TO HELP IMPROVE OSTEOARTHRITIS MANAGEMENT Haleon and University of Sydney launch 5-Year fellowship to research efficacy of dietary supplements

SEGMENT
Filmed in Sydney and online | February 2025

INTERVIEWS
Professor David Hunter,
Florance and Cope Chair of Rheumatology
Co-Director Sydney Musculoskeletal Health Flagship,
University of Sydney

Dr Bincy Thampi,
Medical & Scientific Affairs Lead
Haleon ANZ

Osteoarthritis is a leading cause of disability affecting over 2 million Australians, according to Australian Institute of Health and Welfare report on Chronic musculoskeletal conditions (2024) and 595 million people globally, according to BD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020. It represents a significant public health burden that diminishes quality of life among ageing populations. 

Consumer healthcare company Haleon is sponsoring a five-year named fellowship program at the University of Sydney that will investigate the therapeutic role of supplements in managing osteoarthritis symptoms and digital health technologies that improve mobility. 

The fellowship will fund a postdoctoral researcher to work under the guidance of world leading osteoarthritis expert, rheumatologist and researcher Professor David Hunter.  

Australian Health Journal spoke with Professor Hunter who said the research collaboration represents a shared focus and investment in improving osteoarthritis management: “This is a disabling disease that has a huge impact on the people affected.”  

“A collaborative effort between researchers and manufacturers will drive innovation and hopefully improve the lives of those impacted by this devastating disease. Use of supplements and natural ingredients in managing osteoarthritis is an exciting area with a lot of potential. I’m not aware of any other long-term, five-year projects of this nature that has osteoarthritis as its focus,” said Hunter.  

Haleon and the University of Sydney have a shared goal of finding better management strategies for osteoarthritis and developing better outcomes for the people affected.  

Dr Bincy Thampi, Medical & Scientific Affairs Lead at Haleon ANZ, also spoke with Australian Health Journal and says, “Haleon has a strong commitment to scientific research that drives innovative self-care and improves consumer health outcomes.”

“This partnership illustrates Haleon’s commitment to advancing trusted science for our products to better everyday health and we’re excited to see where this partnership with University of Sydney leads,” said Dr Thampi.